Pac Premier
Giving Guide
You are here:  Home  >  Latest news  >  Current Article

FDA OKs Aranesp for pre-dialysis patients

By   /   Monday, October 25th, 2010  /   Comments Off on FDA OKs Aranesp for pre-dialysis patients

    Print       Email

Amgen’s anemia treatment Aranesp is safe for kidney patients whose disease doesn’t require dialysis, a federal panel announced Oct. 18 in response to a study that found the drug could increase stroke risk in those patients.

Outside advisers to the U.S. Food and Drug Administration said the treatment shouldn’t be withdrawn or limited to a “rescue therapy” because of the recent study, Bloomberg News reported.

Aranesp accounts for 18 percent of revenue at Thousand Oaks-based Amgen. Eliminating pre-dialysis use may shave $200 million to $400 million from annual sales, or 5 to 10 cents from per-share earnings, an analyst told Bloomberg.

Are you a subscriber? If not, sign up today for a four-week FREE trial or subscribe and receive the Book of Lists free with your purchase.

    Print       Email

You might also like...

Limoneira, Calavo both report earnings growth as produce industry continues recovery

Read More →